Umeclidinium

Drug Profile

Umeclidinium

Alternative Names: 573719; Ellipta Incruse; Encruse Ellipta; GSK-573719; Incruse; Incruse Ellipta; UMEC; Umeclidinium bromide

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Benzhydryl compounds; Bronchodilators; Quinuclidines; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma; Hyperhidrosis

Most Recent Events

  • 03 Mar 2017 Adverse events data from a phase IIa trial in Hyperhidrosis presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD-2017)
  • 17 Feb 2017 Umeclidinium is still in phase II trials for Asthma in USA (NCT01573624) (NCT01641692)
  • 17 Feb 2017 No development reported - Phase-II for Asthma (Monotherapy) in Bulgaria, Germany, Mexico, Peru, Poland (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top